Main Article Content
Abstract
L’ostéomalacie est un défaut de minéralisation osseuse. Elle peut être d’étiologie multifactorielle. Nous rapportons l’observation d’une patiente de 52 ans, hospitalisée pour des douleurs osseuses diffuses évoluant depuis un an. Suivie pour une infection par le VIH depuis 10 ans, elle était traitée par une trithérapie associant le Tenofovir, l’Efavirenz et la Lavimudine depuis 6 ans. Elle a présenté une perturbation du métabolisme phospho-calcique et des anomalies osseuses telles que des pseudo fractures, rattachées à une ostéomalacie secondaire à un syndrome de Fanconi favorisé par le tenofovir.
ABSTRACT
Osteomalacia is a defect in bone mineralization. It can be of multifactorial aetiologies. We report the case of 52 year-old patient, hospitalized for diffuse bone pain evolving for one year. Followed for an HIV infection since 10 years, she had been treated with triple therapy combining Tenofovir, Efavirenz and Lamivudine for 6 years. She presented a disturbance of calcium phosphate metabolism and bone abnormalities such as pseudo fractures, related to osteomalacia secondary to Fanconi syndrome. Fanconi syndrome was induced by long course treatment with Tenofovir.
Keywords
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
- Laroche M. Ostéomalacie. Rhumatologie pour le Praticien. Elsevier. 2018. p. 177 80. Disponible sur: https://linkinghub.elsevier.com/retrieve/pii/B9782294748325000154.
- Bhan A, Rao AD, Rao DS. Osteomalacia as a Result of Vitamin D Deficiency. Endocrinol Metab Clin North Am. 2010;39(2):321 31.
- Medland NA, Chow EP, Walker RG, Chen M, Read TR, Fairley CK. Incidence of renal Fanconi syndrome in patients taking antiretroviral therapy including tenofovir disoproxil fumarate. Int J STD AIDS. 2018;29(3):227 36.
- Peyrière H, Reynes J, Rouanet I, Daniel N, De Boever CM, Mauboussin JM, et al. Renal Tubular Dysfunction Associated With Tenofovir Therapy: Report of 7 Cases. J AIDS. 2004;35(3):269 73.
- Earle KE, Seneviratne T, Shaker J, Shoback D. Fanconi’s syndrome in HIV+ adults: report of three cases and literature review. J Bone Miner Res. 2004;19(5):714 21.
- Mateo L, Holgado S, Mariñoso ML, Pérez-Andrés R, Bonjoch A, Romeu J, et al. Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients. Clinical Rheumatology. 2016;35(5):1271 9.
- Rao M, Dadey L, Glowa T, Veldkamp P. Fanconi Syndrome Leading to Hypophosphatemic Osteomalacia Related to Tenofovir Use. Infectious Disease Reports. 2021;13(2):448 53.
- Priemel M, Von Domarus C, Klatte TO, Kessler S, Schlie J, Meier S, et al. Bone mineralization defects and vitamin D deficiency: Histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res. 2010;25(2):305 12.
- Mogire RM, Mutua A, Kimita W, Kamau A, Bejon P, Pettifor JM, et al. Prevalence of vitamin D deficiency in Africa: a systematic review and meta-analysis. The Lancet Global Health. 2020;8(1):e134 42.
- Tangoh DA, Apinjoh TO, Mahmood Y, Nyingchu RV, Tangunyi BA, Nji EN, et al. Vitamin D Status and Its Associated Risk Factors among Adults in the Southwest Region of Cameroon. Journal of Nutrition and Metabolism. 2018;2018:1 9.
- Fukumoto S, Ozono K, Michigami T, Minagawa M, Okazaki R, Sugimoto T, et al. Pathogenesis and diagnostic criteria for rickets and osteomalacia—proposal by an expert panel supported by the Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research, and the Japan Endocrine Society. J Bone Miner Metab. 2015;33(5):467 73.
- Rodriguez-Nóvoa S, Alvarez E, Labarga P, Soriano V. Renal toxicity associated with tenofovir use. Expert Opinion on Drug Safety. 2010;9(4):545 59.
- Phuphuakrat A, Pasomsub E, Chantratita W, Mahasirimongkol S, Disthabanchong S, Sungkanuparph S, et al. Risk Factors of Renal Tubular Dysfunction in Thai People Living with HIV Receiving Tenofovir Disoproxil Fumarate. J Int Assoc Provid AIDS Care. 2022;21:23259582221134750.
- Mtisi TJ, Ndhlovu CE, Maponga CC, Morse GD. Tenofovir-associated kidney disease in Africans: a systematic review. AIDS Res Ther. 2019;16(1):12.
- Tjen-A-Looi A. Hypophosphatemic Osteomalacia Associated with Tenofovir Use in HIVInfected Patients: A Case Series and Review of the Literature. J AIDS Clinic Res. 2012;01(S4).
- Wanner DP, Tyndall A, Walker UA. Tenofovir-induced osteomalacia. Clin Exp Rheumatol. 2009;27(6):1001 3.
- Gifre L, Peris P, Monegal A, Martinez De Osaba MJ, Alvarez L, Guañabens N. Osteomalacia revisited: A report on 28 cases. Clin Rheumatol. 2011;30(5):639 45.
- Martin A, Moore C, Mallon PWG, Hoy J, Emery S, Belloso W, et al. Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy. AIDS. 2013;27(15):2403 11.
- Aydın OA, Karaosmanoglu HK, Karahasanoglu R, Tahmaz M, Nazlıcan O. Prevalence and risk factors of osteopenia/osteoporosis in Turkish HIV/AIDS patients. The Brazilian Journal of Infectious Diseases. 2013;17(6):707 11.
- Jean G, Souberbielle J, Chazot C. Vitamin D in Chronic Kidney Disease and Dialysis Patients. Nutrients. 2017;9(4):328.
- Holick MF. The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention. Rev Endocr Metab Disord. 2017;18(2):153 65.
- Am G. Évolution Immuno-Virologique des Personnes Vivant avec le Virus d’Immunodéficience Humaine sous Traitement Antirétroviral Incarcérées à la Maison d’Arrêt de Niamey. Health Sci Dis. 2022;23(9): 61-66.
- Bonjoch A, Echeverría P, Perez-Alvarez N, Puig J, Estany C, Clotet B, et al. High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy. Antiviral Research. 2012;96(1):65 9.
References
Laroche M. Ostéomalacie. Rhumatologie pour le Praticien. Elsevier. 2018. p. 177 80. Disponible sur: https://linkinghub.elsevier.com/retrieve/pii/B9782294748325000154.
Bhan A, Rao AD, Rao DS. Osteomalacia as a Result of Vitamin D Deficiency. Endocrinol Metab Clin North Am. 2010;39(2):321 31.
Medland NA, Chow EP, Walker RG, Chen M, Read TR, Fairley CK. Incidence of renal Fanconi syndrome in patients taking antiretroviral therapy including tenofovir disoproxil fumarate. Int J STD AIDS. 2018;29(3):227 36.
Peyrière H, Reynes J, Rouanet I, Daniel N, De Boever CM, Mauboussin JM, et al. Renal Tubular Dysfunction Associated With Tenofovir Therapy: Report of 7 Cases. J AIDS. 2004;35(3):269 73.
Earle KE, Seneviratne T, Shaker J, Shoback D. Fanconi’s syndrome in HIV+ adults: report of three cases and literature review. J Bone Miner Res. 2004;19(5):714 21.
Mateo L, Holgado S, Mariñoso ML, Pérez-Andrés R, Bonjoch A, Romeu J, et al. Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients. Clinical Rheumatology. 2016;35(5):1271 9.
Rao M, Dadey L, Glowa T, Veldkamp P. Fanconi Syndrome Leading to Hypophosphatemic Osteomalacia Related to Tenofovir Use. Infectious Disease Reports. 2021;13(2):448 53.
Priemel M, Von Domarus C, Klatte TO, Kessler S, Schlie J, Meier S, et al. Bone mineralization defects and vitamin D deficiency: Histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res. 2010;25(2):305 12.
Mogire RM, Mutua A, Kimita W, Kamau A, Bejon P, Pettifor JM, et al. Prevalence of vitamin D deficiency in Africa: a systematic review and meta-analysis. The Lancet Global Health. 2020;8(1):e134 42.
Tangoh DA, Apinjoh TO, Mahmood Y, Nyingchu RV, Tangunyi BA, Nji EN, et al. Vitamin D Status and Its Associated Risk Factors among Adults in the Southwest Region of Cameroon. Journal of Nutrition and Metabolism. 2018;2018:1 9.
Fukumoto S, Ozono K, Michigami T, Minagawa M, Okazaki R, Sugimoto T, et al. Pathogenesis and diagnostic criteria for rickets and osteomalacia—proposal by an expert panel supported by the Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research, and the Japan Endocrine Society. J Bone Miner Metab. 2015;33(5):467 73.
Rodriguez-Nóvoa S, Alvarez E, Labarga P, Soriano V. Renal toxicity associated with tenofovir use. Expert Opinion on Drug Safety. 2010;9(4):545 59.
Phuphuakrat A, Pasomsub E, Chantratita W, Mahasirimongkol S, Disthabanchong S, Sungkanuparph S, et al. Risk Factors of Renal Tubular Dysfunction in Thai People Living with HIV Receiving Tenofovir Disoproxil Fumarate. J Int Assoc Provid AIDS Care. 2022;21:23259582221134750.
Mtisi TJ, Ndhlovu CE, Maponga CC, Morse GD. Tenofovir-associated kidney disease in Africans: a systematic review. AIDS Res Ther. 2019;16(1):12.
Tjen-A-Looi A. Hypophosphatemic Osteomalacia Associated with Tenofovir Use in HIVInfected Patients: A Case Series and Review of the Literature. J AIDS Clinic Res. 2012;01(S4).
Wanner DP, Tyndall A, Walker UA. Tenofovir-induced osteomalacia. Clin Exp Rheumatol. 2009;27(6):1001 3.
Gifre L, Peris P, Monegal A, Martinez De Osaba MJ, Alvarez L, Guañabens N. Osteomalacia revisited: A report on 28 cases. Clin Rheumatol. 2011;30(5):639 45.
Martin A, Moore C, Mallon PWG, Hoy J, Emery S, Belloso W, et al. Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy. AIDS. 2013;27(15):2403 11.
Aydın OA, Karaosmanoglu HK, Karahasanoglu R, Tahmaz M, Nazlıcan O. Prevalence and risk factors of osteopenia/osteoporosis in Turkish HIV/AIDS patients. The Brazilian Journal of Infectious Diseases. 2013;17(6):707 11.
Jean G, Souberbielle J, Chazot C. Vitamin D in Chronic Kidney Disease and Dialysis Patients. Nutrients. 2017;9(4):328.
Holick MF. The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention. Rev Endocr Metab Disord. 2017;18(2):153 65.
Am G. Évolution Immuno-Virologique des Personnes Vivant avec le Virus d’Immunodéficience Humaine sous Traitement Antirétroviral Incarcérées à la Maison d’Arrêt de Niamey. Health Sci Dis. 2022;23(9): 61-66.
Bonjoch A, Echeverría P, Perez-Alvarez N, Puig J, Estany C, Clotet B, et al. High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy. Antiviral Research. 2012;96(1):65 9.